Literature DB >> 17516871

Botulinum neurotoxin type A in facial aesthetics.

Koenraad L V De Boulle1.   

Abstract

Injection of botulinum neurotoxin type A has rapidly become the most common non-surgical cosmetic procedure performed, due to its exceptional safety profile, as well as its ability to rejuvenate and enhance a number of facial areas. There are several marketed botulinum neurotoxin preparations, but products are not interchangeable as each possesses distinctive characteristics that are attributed to the unique toxin purification and manufacturing processes. These differences can emerge in the form of potency, duration of effect and the potential for migration outside targeted tissue, causing unwanted effects. However, although there are established preclinical pharmacologic and therapeutic differences between products, there are few well-controlled clinical comparisons in facial aesthetics. It is important for clinicians using these products to understand these differences as they relate to achieving desired outcomes for patients who seek improved facial aesthetics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17516871     DOI: 10.1517/14656566.8.8.1059

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  4 in total

Review 1.  Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction.

Authors:  Koenraad De Boulle; Steven Fagien; Boris Sommer; Richard Glogau
Journal:  Clin Interv Aging       Date:  2010-04-26       Impact factor: 4.458

2.  Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.

Authors:  Saedeh Dadgar; Zack Ramjan; Wely B Floriano
Journal:  J Med Chem       Date:  2013-03-29       Impact factor: 7.446

3.  [Botulinum toxin in dermatology].

Authors:  W G Philipp-Dormston
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

4.  A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects.

Authors:  Kiyonori Harii; Makoto Kawashima
Journal:  Aesthetic Plast Surg       Date:  2008-07-29       Impact factor: 2.326

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.